Literature DB >> 15783118

Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma.

Attalla Farag El-Kott1, Abdalla Mohamed Khalil, Ayman El-Meghawry El-Kenawy.   

Abstract

BACKGROUND: The authors found previously that plasma levels of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) were elevated in patients with bladder carcinoma and were associated with features of biologically aggressive disease. The present study has been performed to analyze the expressions of two antigens by immunohistochemical staining in bladder transitional cell carcinoma. PATIENTS AND METHODS: The tumors from 72 men and 28 women with a mean age 46.15 years (range 30-67 years) were examined. Paraffin sections of 5 microm thickness were prepared for immunohistochemical staining of uPA and uPAR antigens. Age, sex, tumor grade and stage, DNA ploidy, lymph node status, and metastases were evaluated in relation to outcome. Univariate and multivariate analysis of survival were performed.
RESULTS: The overall 5-year survival was 66%. Thirty six and 46 cases were positive for uPA and uPAR expressions, respectively. In univariate analysis, tumor stage, lymph node status, metastases, uPA and uPAR have a significant impact on the survival for these patients. In a Cox proportional hazard model, uPAR sustained its significant impact on survival.
CONCLUSIONS: These findings suggest that uPAR is an independent additional prognostic factor in patients with transitional cell carcinoma of the bladder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15783118     DOI: 10.1007/s11255-004-8684-3

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  27 in total

1.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

Review 2.  Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness.

Authors:  F Blasi
Journal:  Bioessays       Date:  1993-02       Impact factor: 4.345

Review 3.  Current bladder tumor tests: does their projected utility fulfill clinical necessity?

Authors:  V B Lokeshwar; M S Soloway
Journal:  J Urol       Date:  2001-04       Impact factor: 7.450

Review 4.  Bladder cancer.

Authors:  H Ozen; M C Hall
Journal:  Curr Opin Oncol       Date:  2000-05       Impact factor: 3.645

5.  Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.

Authors:  A Stahl; B M Mueller
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

6.  Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms.

Authors:  W M Murphy; M S Soloway; A F Jukkola; W N Crabtree; K S Ford
Journal:  Cancer       Date:  1984-04-01       Impact factor: 6.860

7.  The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer.

Authors:  Y Hasui; K Marutsuka; S Nishi; S Kitada; Y Osada; A Sumiyoshi
Journal:  J Urol       Date:  1994-01       Impact factor: 7.450

8.  Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.

Authors:  Y Hasui; J Suzumiya; K Marutsuka; A Sumiyoshi; S Hashida; E Ishikawa
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

9.  Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.

Authors:  M V Cubellis; T C Wun; F Blasi
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

10.  Upregulation of urokinase receptor expression on migrating endothelial cells.

Authors:  M S Pepper; A P Sappino; R Stöcklin; R Montesano; L Orci; J D Vassalli
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

View more
  5 in total

1.  Predictive value of EGF and uPAR for chemoradiotherapy response and survival in patients with esophageal squamous cell carcinoma.

Authors:  Xi Chen; Hui Wei; Dong Qian; Yuwen Wang; Yong Guan; Puchun Er; Yongchun Song; Ningbo Liu; Jun Wang; Lujun Zhao; Zhiyong Yuan; Ping Wang; Qingsong Pang; Wencheng Zhang
Journal:  Ann Transl Med       Date:  2020-09

2.  HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor.

Authors:  Ahmed H Mekkawy; David L Morris; Mohammad H Pourgholami
Journal:  J Oncol       Date:  2012-01-17       Impact factor: 4.375

3.  Relationship between the genetic expression of WTAP and bladder cancer and patient prognosis.

Authors:  Lezhong Chen; Xinghuan Wang
Journal:  Oncol Lett       Date:  2018-10-05       Impact factor: 2.967

Review 4.  Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.

Authors:  Nico C Grossmann; Victor M Schuettfort; Benjamin Pradere; Marco Moschini; Fahad Quhal; Hadi Mostafaei; Francesco Soria; Satoshi Katayama; Ekaterina Laukhtina; Keiichiro Mori; Reza Sari Motlagh; Cédric Poyet; Mohammad Abufaraj; Pierre I Karakiewicz; Shahrokh F Shariat; David D'Andrea
Journal:  Onco Targets Ther       Date:  2021-01-13       Impact factor: 4.147

5.  uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180.

Authors:  Harvey W Smith; Pierfrancesco Marra; Christopher J Marshall
Journal:  J Cell Biol       Date:  2008-08-25       Impact factor: 10.539

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.